T1	p 100 133	patients with early breast cancer
T2	p 314 347	patients with early breast cancer
T3	i 36 39	FEC
T4	i 243 253	epirubicin
T5	i 474 522	fluorouracil/epirubicin/cyclophosphamide ( FEC )
T6	i 618 621	FEC
T7	i 720 723	FEC
T8	i 777 780	FEC
T9	i 791 794	FEC
T10	i 886 899	pegfilgrastim
T11	i 1179 1182	FEC
T12	i 1242 1245	FEC
T13	i 1413 1416	FEC
T14	i 1524 1527	FEC
T15	i 1759 1762	FEC
T16	i 1867 1870	FEC
T17	i 1882 1885	FEC
T18	o 1003 1070	proportion of subjects receiving > or =85 % relative dose intensity
T19	o 1317 1331	adverse events
T20	o 1439 1448	diarrhoea
T21	o 1461 1486	haematological toxicities
T22	o 1569 1588	febrile neutropenia
T23	o 1657 1698	liver enzymes and gastrointestinal events
T24	o 1784 1837	serious adverse events ( vomiting and throat oedema )